(Q37800603)

23 August 2017

title

Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC (English)

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

3 August 2024

1 reference

Alex Chang

1

1 reference

23 August 2017

language of work or name

1 reference

16 October 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0169500210004307?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

https://api.elsevier.com/content/article/PII:S0169500210004307?httpAccept=text/plain

3 August 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

3 August 2024

1 reference

23 August 2017

volume

71

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

3-10

1 reference

23 August 2017

cites work

Cancer statistics, 2010

2

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Global cancer statistics, 2002

3 August 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

3 August 2024

Cancer statistics, 2008

4

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control

3 August 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

3 August 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

3 August 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

3 August 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired

3 August 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer

3 August 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer

3 August 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

3 August 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation

3 August 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

3 August 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer

3 August 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.

3 August 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial

3 August 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature

3 August 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer

3 August 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

3 August 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

3 August 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer

3 August 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

BRCA1: a novel prognostic factor in resected non-small-cell lung cancer

3 August 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression

3 August 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation

3 August 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin

3 August 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Mechanism of action of antitumor drugs that interact with microtubules and tubulin

3 August 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?

3 August 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer

3 August 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol

3 August 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

3 August 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

3 August 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel

3 August 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Chemoresistance in non-small cell lung cancer

3 August 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Class III -Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10

3 August 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site

3 August 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

3 August 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Mechanisms of resistance to camptothecins.

3 August 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity

3 August 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients

3 August 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

3 August 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene

3 August 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Novel cytotoxic agents for non-small cell lung cancer

3 August 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies

3 August 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer

3 August 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment

3 August 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer

3 August 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

3 August 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer

3 August 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer

3 August 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

A phase II study of ABT-751 in patients with advanced non-small cell lung cancer

3 August 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy

3 August 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells

3 August 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography

3 August 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions

3 August 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Molecular mechanisms of patupilone resistance

3 August 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies

3 August 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

3 August 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

3 August 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

3 August 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.022

3 August 2024

Identifiers

1 reference

23 August 2017

1 reference